A biologic called Ilaris, an Interleukin-1 (IL-1) beta inhibitor, has been approved for Systemic Juvenile Arthritis, Still’s Disease. Ilaris is already approved to treat other similar autoinflammatory diseases, such as CAPS (cryopyrin-associated period syndromes).
For those of us whose diseases best respond to IL-1 drugs (Kineret), it’s great to have another option on the market for us now and hopefully will make it easier for insurance to cover the medication (no more off-label use). A good day for JIA!
Click to read more.